Try our Advanced Search for more refined results

February 21, 2018

Amgen Inc. v. Alex Azar, II, et al

Track this case

Case Number:

18-5046

Court:

Appellate - DC Circuit

Nature of Suit:

2890 Other Statutory Actions

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. September 28, 2018

    Sensipar Exclusivity Expires, Ending Amgen's DC Circ. Fight

    Amgen Inc. and the U.S. Food and Drug Administration have asked the D.C. Circuit to end their case debating whether the drugmaker should get extended exclusivity for its blockbuster calcium-control drug Sensipar, as that exclusivity period has already lapsed.

3 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!